UPDATE Hematologie / Onkologie 2024
ESMO-kongres 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Jy gebruik 'n ouer weergawe van jou webblaaier, so sommige kenmerke sal dalk nie behoorlik vertoon nie.
MINIMALE Vereistes: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 verbeter rPFS vir metastatiese kastrasiebestande prostaatkankerpasiënte wat taksaan-naïef is23 Okt 2023Die PSMAfore-proef se bevindinge word beperk deur die feit dat hulle nie 'n voordeel in terme van OS toon nie.
Registreer vir kaartjies of stalletjies
Plekkaart en hotelle rondom
Munich - Holiday Inn Munich - Stadsentrum, Beiere, Duitsland Munich - Holiday Inn Munich - Stadsentrum, Beiere, Duitsland
Teken In